Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Axonklinikken
Oslo, Norway
- Ownership
- Private
- Development stage
- Other
01
Overview
Axonklinikken demonstrated significant clinical improvements in depression, anxiety, PTSD, and addiction using ketamine-assisted psychotherapy, reporting rapid onset of effect, relatively few side effects, and success rates above 70% in depression and about two-thirds in PTSD[4].
- Therapeutic areas
- NeurologyPsychiatry
- Modalities
- Small moleculeKetamine-assisted psychotherapyEsketamine-assisted psychotherapy
- Industry
- Non-Academic Healthcare
02
Partnerships
Public health institutions in Norway (e.g., Sykehuset Østfold, DPS Nordre Østfold)University of Exeter (via Awakn’s KARE trial license)
Beyond the preview
Go deeper on Axonklinikken.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Axonklinikken.